Successful Completion of Long-Term Human Safety Trial Of KT-939
Suzhou, 7 September, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term human safety trial of KT-939, an in-house developed novel and highly effective tyrosinase inhibitor for inhibiting melanin production, was successfully completed on 4 September 2026. A total of 114 subjects received continuous administration of KT-939 for 52 consecutive weeks, and preliminary data indicate that none of them experienced any adverse skin reactions, in line with the 28 week interim clinical results, fully demonstrating the excellent safety profile of KT-939.
The long-term safety trial is an open-label, single-arm, single-center study designed to evaluate the potential for long-term topical use of cosmetics containing the raw material KT-939 to induce adverse skin reactions in humans, with a primary focus on the safety of topical application of 0.2% KT-939 for 52 consecutive weeks.
As a next generation innovative whitening and freckle-removing raw material, KT-939 is subject to registration and approval by the National Medical Products Administration (“NMPA”) prior to market launch. The long-term safety trial was completed under the guidance of the Methods for Long-Term Human Use Testing for cosmetic raw materials, issued by the NMPA on 18 June 2026, and its results constitute one of the most critical components of the registration application materials for KT-939.
The Company is actively advancing the registration application process, and upon obtaining the long-term safety trial results, plans to complete the submission of all application materials to the NMPA as soon as practicable.
About Kintor Pharmaceutical Limited
Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas, and establish a “troika” business model formed by R&D business of innovative topical drugs, B2B business of functional cosmetic raw materials and B2C business of functional cosmetic products. After several years' development, the Company has developed diverse product pipeline built on dermatology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
